General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Severe eosinophilic asthma, add-on maintenance treatment of in children (aged 6 years and older)
Last updated April 18, 2024
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Severe chronic rhinosinusitis with nasal polyps
Last updated April 18, 2024
Abecma (idecabtagene vicleucel)
Status:
Negotiations were not pursued
Manufacturer:
Celgene Inc.
Indication:
Multiple myeloma (MM) in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and who are refractory to their last treatment.
Last updated April 18, 2024
Status:
Concluded with an LOI
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Ulcerative Colitis
Last updated March 20, 2024
Status:
Concluded with an LOI
Manufacturer:
Kyowa Kirin Canada, Inc.
Indication:
Mycosis Fungoides (MF), S�zary Syndrome (SS)
Last updated March 13, 2024
Imfinzi and Imjudo (durvalumab and tremelimumab)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Unresectable hepatocellular carcinoma (uHCC) in adult patients who require systemic therapy, first-line treatment
Last updated February 28, 2024
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine-based chemotherapy
Last updated February 28, 2024
Status:
Negotiations were not pursued
Manufacturer:
Alexion Pharma GmbH
Indication:
Generalized Myasthenia Gravis, AChR antibody-positive
Last updated February 27, 2024
Status:
Concluded with an LOI
Manufacturer:
Jamp Pharma Corporation
Indication:
Multiple Indications
Last updated February 9, 2024
Enhertu (trastuzumab deruxtecan)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Breast cancer, monotherapy for the treatment of adult patients, unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-)
Last updated February 2, 2024